Welcome to our dedicated page for Acorda Therapeutics news (Ticker: ACOR), a resource for investors and traders seeking the latest updates and insights on Acorda Therapeutics stock.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is a biopharmaceutical company focused on developing therapies for neurological disorders through innovative research and strategic collaborations. This dedicated news hub provides investors and stakeholders with timely updates on corporate developments, clinical research milestones, and regulatory progress.
Access the latest press releases, financial reports, and partnership announcements in one centralized location. Our curated collection includes updates on therapeutic advancements, management changes, and market-related developments relevant to Acorda's mission of restoring neurological function.
Key content categories include clinical trial results, FDA regulatory updates, intellectual property developments, and financial performance reports. Users will find essential information about therapeutic pipeline progress, research collaborations, and strategic business decisions impacting Acorda's position in the biotechnology sector.
Bookmark this page for convenient access to verified information directly from Acorda Therapeutics and respected financial news sources. Check back regularly for objective updates that matter to investors tracking neurological therapeutics innovation.
Acorda Therapeutics (NASDAQ: ACOR) announces a conference call to discuss its Q2 2021 financial results on August 5 at 4:30 p.m. ET. Participants can register for the webcast and call via provided links. A replay will be available from 7:30 p.m. ET on August 5 until September 4. Acorda develops therapies for neurological disorders, with products like INBRIJA® for Parkinson's disease and AMPYRA® for multiple sclerosis. The company cautions that forward-looking statements depend on various risks, including market competition and regulatory challenges.
Acorda Therapeutics (Nasdaq: ACOR) has partnered with Esteve Pharmaceuticals to distribute INBRIJA® (levodopa inhalation powder) in Spain. This medication targets intermittent motor fluctuations in Parkinson’s disease patients. Acorda will receive a significant double-digit percentage of the selling price, while Esteve holds exclusive distribution rights, planning to launch INBRIJA in Q4 2022. With around 300,000 Parkinson's patients in Spain, this partnership aims to enhance treatment options for those in need.
Acorda Therapeutics (Nasdaq: ACOR) has fully repaid its 1.75% Convertible Senior Notes amounting to $69 million ahead of maturity using cash on hand. This repayment is seen as a significant milestone following the company's earlier sale of its manufacturing operations. CEO Ron Cohen emphasized a focus on enhancing the growth of INBRIJA and AMPYRA while maintaining financial discipline to reach cash flow breakeven. Acorda develops treatments for neurological disorders, notably highlighting INBRIJA for Parkinson's disease.
Acorda Therapeutics (Nasdaq: ACOR) reported a GAAP net loss of $33.5 million, or $3.53 per diluted share, for Q1 2021, compared to a $6.5 million net loss in Q1 2020. Revenue for INBRIJA increased to $5 million, up from $4.4 million year-over-year, while AMPYRA sales remained stable at $20.3 million. R&D expenses decreased to $4.7 million, and SG&A expenses fell to $34 million. The company expects AMPYRA revenue between $75-$85 million for 2021 and operating expenses of $130-$140 million. Acorda aims to be cash-flow neutral by the end of 2022.
Acorda Therapeutics (NASDAQ: ACOR) will conduct a conference call and webcast on May 6, 2021, at 4:30 p.m. ET, to discuss its first quarter 2021 update and financial results. This event includes a new pre-registration process for participants. A replay of the call will be available from 7:30 p.m. ET on the same day until June 3, 2021. Acorda focuses on developing therapies for neurological disorders, including INBRIJA® for Parkinson's disease and AMPYRA® for multiple sclerosis, utilizing its ARCUS® pulmonary delivery system. Forward-looking statements are included, highlighting potential risks to business operations.
Acorda Therapeutics (NASDAQ: ACOR) has partnered with culinary icon Zarela Martinez to launch “A Taste for Life with Zarela” in honor of Parkinson’s Awareness Month. The video series highlights Zarela's personal journey with Parkinson’s disease and offers recipes promoting healthy living. Zarela, diagnosed in 2004, shares her experience managing symptoms with nutrition and exercise, alongside the use of INBRIJA® (levodopa inhalation powder) since its launch in 2019. INBRIJA is the first inhaled levodopa for managing OFF episodes in Parkinson's patients.
Acorda Therapeutics (NASDAQ: ACOR) announces that CEO Ron Cohen will present at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9th & 10th. The event will showcase advancements in therapies aimed at neurological disorders, including Acorda's products like INBRIJA and AMPYRA. INBRIJA is designed for intermittent treatment of OFF episodes in Parkinson’s disease. The company highlights potential risks, including market competition and manufacturing challenges, affecting future performance.
Acorda Therapeutics (Nasdaq: ACOR) reported its Q4 and full-year 2020 financial results, highlighting significant changes. The company sold its manufacturing operations for $80 million, resulting in an expected annual operating expense reduction of $40 million. INBRIJA net revenue increased to $9.3 million in Q4 2020, up from $6.1 million in Q4 2019, while AMPYRA revenue fell to $25.3 million from $40.8 million. Acorda posted a GAAP net loss of $83 million in Q4 2020, compared to a profit of $65.7 million in Q4 2019. Looking ahead, Acorda projects AMPYRA revenue of $75-$85 million for 2021.
Acorda Therapeutics (NASDAQ: ACOR) will host a conference call and webcast on March 4, 2021, at 4:30 p.m. ET to discuss its fourth quarter and annual financial results for 2020. Registrants will receive a confirmation email with participation details. A replay of the call will be available until April 3, 2021. Acorda develops therapies for neurological disorders, including INBRIJA and AMPYRA. The company warns of risks affecting future performance, including the COVID-19 pandemic and market competition.
Acorda Therapeutics (Nasdaq: ACOR) announced the resignation of David Lawrence, Chief of Business Operations and principal accounting officer, effective mid-March 2021. Lawrence is moving to a leadership role in an early-stage biotech firm. Acorda's President, Ron Cohen, acknowledged his 22 years of service. Lawrence stated he leaves the company in an excellent position following recent financial improvements. Robert Morales will be the interim principal accounting and financial officer. Acorda focuses on therapies for neurological disorders, including its products INBRIJA and AMPYRA.
